dc.contributor.author | Mote, PA | en_US |
dc.contributor.author | Gompel, A | en_US |
dc.contributor.author | Howe, C | en_US |
dc.contributor.author | Hilton, HN | en_US |
dc.contributor.author | Sestak, I | en_US |
dc.contributor.author | Cuzick, J | en_US |
dc.contributor.author | Dowsett, M | en_US |
dc.contributor.author | Hugol, D | en_US |
dc.contributor.author | Forgez, P | en_US |
dc.contributor.author | Byth, K | en_US |
dc.contributor.author | Graham, JD | en_US |
dc.contributor.author | Clarke, CL | en_US |
dc.date.accessioned | 2015-06-08T10:39:21Z | |
dc.date.available | 2015-04-18 | en_US |
dc.date.issued | 2015-06 | en_US |
dc.identifier.issn | 0167-6806 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/7627 | |
dc.format.extent | 309 - 318 | en_US |
dc.relation.ispartof | BREAST CANCER RESEARCH AND TREATMENT | en_US |
dc.subject | Breast tumors | en_US |
dc.subject | Progesterone receptors A and B | en_US |
dc.subject | Lifetime endocrine exposures | en_US |
dc.subject | Disease-free survival | en_US |
dc.subject | TransATAC trial | en_US |
dc.title | Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial | en_US |
dc.type | Article | |
dc.identifier.doi | 10.1007/s10549-015-3397-0 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000354499200008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 2 | en_US |
pubs.notes | Not known | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 151 | en_US |